Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis

Inclusion Criteria:

- Chronic scalp psoriasis for at least the previous six months

- Moderate to severe scalp psoriasis as defined by a PSSI score of ≥12 and 30% or higher
of scalp surface area affected

- Must be candidates for systemic therapy, which means having scalp psoriasis
inadequately controlled by topical treatments (corticosteroids), and/or phototherapy,
and/or previous systemic therapy.

Exclusion Criteria:

- Forms of psoriasis other than chronic plaque

- Drug-induced psoriasis (e.g., new onset or current exacerbation from β-blockers,
calcium channel inhibitors)

- Ongoing use of prohibited treatments (e.g., topical or systemic corticosteroids, UV
therapy)

- Prior exposure to secukinumab (AIN457) or any other biologic drug directly targeting
IL17A or IL-17RA receptors

- Use of other investigational drugs within 30 days prior to study entry, or within a
period of 5 half-lives of the investigational treatment, whichever is longer

- Active, ongoing inflammatory diseases other than psoriasis that might confound the
evaluation of the benefit of secukinumab

- Active system infections (with the exception of the common cold) during the two weeks
prior to starting study treatment

- Other protocol-defined inclusion/exclusion criteria may apply